KPV
KPV Tripeptide
Potential Benefits
- Research suggests anti-inflammatory effects through NF-kB pathway inhibition
- Animal studies indicate potential benefits for inflammatory bowel conditions
- May support intestinal barrier function based on preclinical data
- Studies suggest antimicrobial properties
- Does not cause skin pigmentation changes unlike the full alpha-MSH molecule
Recommended Starting Dose
200-500 mcg orally, subcutaneously, or topically (not well-established)
Based on published research protocols. Not a prescription.
Dosing Protocol
Protocols vary by route of administration. Oral: 200-500 mcg 1-2 times daily, often used for gut inflammation. Subcutaneous: 200-500 mcg daily. Topical: applied to affected skin areas. No standardized clinical protocol exists. Cycles of 4-8 weeks are commonly discussed.
DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.
Expected Timeline
Phase 1
Anecdotal reports suggest gut-related improvements within 2-4 weeks. Skin inflammation improvements may be noticed within 1-2 weeks of topical use.
Research Status
The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.
Potential Side Effects
- Very limited human clinical data
- Potential gastrointestinal effects with oral administration
- Injection site reactions possible
- Safety profile is not well-established in humans
- Long-term effects are unknown
More in Immune
Ta1
Thymosin Alpha 1
Thymosin Alpha 1 is a naturally occurring peptide first isolated from thymic tissue. The synthetic version (thymalfasin) is approved in over 35 countries for conditions including hepatitis B, hepatitis C, and as an immune adjuvant. It modulates the immune system by enhancing T-cell function, dendritic cell maturation, and antibody responses.
LL-37
Cathelicidin LL-37
LL-37 is the only human cathelicidin antimicrobial peptide, consisting of 37 amino acids. It is produced by immune cells, epithelial cells, and other tissues as part of the innate immune defense. Beyond direct antimicrobial activity, research suggests it plays roles in immune modulation, wound healing, and inflammation regulation.
Medical Disclaimer
EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.